From Pills to Injections: Comparing the Pharmacokinetics and Clinical Impact of Oral Semaglutide and Injectable GLP-1 Agonists

Abstract

Abstract

Introduction

Type 2 diabetes (T2D) is a prevalent chronic condition affecting over 500 million individuals globally as of 2026, characterized by insulin resistance, progressive pancreatic beta-cell failure, and resultant hyperglycemia. The management of T2D has evolved significantly with the advent of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medications that address multiple pathophysiological aspects of the disease. These agents enhance glucose-dependent insulin secretion, suppress inappropriate glucagon release, slow gastric emptying, and promote satiety, leading to improved glycemic control, weight reduction, and cardiovascular benefits. Initially introduced as injectable therapies, GLP-1 RAs such as exenatide (twice-daily or weekly subcutaneous [SC]), liraglutide (daily SC), dulaglutide (weekly SC), and semaglutide (weekly SC) have demonstrated superior efficacy in clinical trials compared to traditional oral antidiabetic drugs.

Despite their advantages, injectable GLP-1 RAs face barriers to widespread adoption, including needle phobia, injection-site reactions, and inconvenience, which contribute to suboptimal adherence rates reported as low as 40-60% in real-world settings. To overcome these challenges, oral formulations have been developed, with oral semaglutide (Rybelsus®) marking a pivotal advancement as the first orally administered GLP-1 RA, approved by the FDA in 2019 and subsequently by regulatory bodies worldwide. This formulation utilizes an innovative absorption enhancer to enable gastrointestinal uptake of the peptide, traditionally susceptible to enzymatic degradation and poor permeability.

This narrative review synthesizes the pharmacokinetics (PK), pharmacodynamics (PD), and clinical efficacy of oral semaglutide in comparison with injectable GLP-1 RAs, with a primary focus on pharmacological and clinical dimensions rather than pharmaceutics. Drawing from landmark clinical trial programs such as PIONEER (for oral semaglutide) and SUSTAIN (for SC semaglutide), as well as meta-analyses and real-world evidence up to 2026, we evaluate key outcomes including glycemic control, weight loss, cardiovascular safety, and tolerability. The role of advanced oral delivery systems is discussed contextually to highlight their influence on PK and patient-centered outcomes. Evidence from 20 selected references informs this analysis, aiming to guide clinicians in optimizing T2D therapy amid an expanding therapeutic landscape.

The burden of T2D extends beyond hyperglycemia, encompassing macrovascular complications (e.g., myocardial infarction, stroke) and microvascular issues (e.g., retinopathy, nephropathy). GLP-1 RAs have shown cardiovascular protective effects in large outcome trials, positioning them as preferred agents in patients with established atherosclerotic cardiovascular disease (ASCVD) or high risk, per guidelines from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). Semaglutide, in particular, stands out due to its long half-life and potent receptor activation, offering once-weekly SC or daily oral dosing. Comparative studies underscore the need to balance efficacy, safety, and patient preference, especially as oral options reduce injection-related barriers.

Pharmacology of GLP-1 Receptor Agonists

GLP-1 RAs are synthetic analogs designed to mimic the endogenous incretin hormone GLP-1, which is secreted by intestinal L-cells in response to nutrient ingestion. Native GLP-1 has a short half-life (~2 minutes) due to rapid degradation by dipeptidyl peptidase-4 (DPP-4), necessitating modifications in therapeutic analogs for clinical utility. Semaglutide features an alanine to 2-aminoisobutyric acid substitution at position 8 for DPP-4 resistance, a lysine to arginine change at position 34, and attachment of a C18 fatty diacid chain via a spacer, enabling strong albumin binding (>99%) and prolonged action.

Pharmacologically, GLP-1 RAs bind to G-protein-coupled GLP-1 receptors expressed on pancreatic beta-cells, alpha-cells, gastric mucosa, and central nervous system regions such as the hypothalamus. Activation stimulates adenylate cyclase, increasing cyclic AMP and promoting glucose-dependent insulin release from beta-cells while inhibiting glucagon secretion from alpha-cells, thus mitigating postprandial hyperglycemia without significant hypoglycemia risk. Gastric emptying delay reduces nutrient absorption rate, contributing to glycemic control, while central effects on appetite centers (e.g., area postrema) enhance satiety and reduce caloric intake.

Semaglutide exhibits high receptor affinity, with an EC50 for cAMP production in the low picomolar range, comparable to or exceeding other GLP-1 RAs like liraglutide (EC50 ~0.1 nM) and dulaglutide. In vitro studies demonstrate semaglutide's superior potency in stimulating insulin secretion and inhibiting glucagon compared to exenatide. Clinically, both oral and SC formulations improve beta-cell function, as measured by homeostasis model assessment (HOMA-B), and reduce hepatic glucose production via glucagon suppression. Additional pleiotropic effects include anti-inflammatory actions (reduced TNF-α, IL-6), improved endothelial function, and natriuresis, underpinning cardiovascular and renal benefits observed in trials.[1][2]

Differences between formulations are minimal in PD, as efficacy is exposure-driven rather than route-specific. Exposure-response analyses show nearly identical relationships for HbA1c and weight loss; at typical levels, SC semaglutide achieves slightly greater HbA1c reduction (-1.62% vs. -1.58% for oral) but comparable weight loss (-3.48% vs. -3.77%). Body weight influences exposure for both, with higher weight linked to reduced levels.[3] Other injectable GLP-1 RAs, such as dulaglutide (a GLP-1-IgG4 fusion protein), offer similar PD but with varying half-lives (4-5 days) and dosing frequencies.

In T2D pathophysiology, GLP-1 RAs address the “incretin defect,” where reduced GLP-1 response contributes to impaired insulin secretion. Long-term use preserves beta-cell mass in preclinical models, potentially delaying disease progression. Clinical pharmacology highlights dose-dependent effects, with higher doses amplifying PD responses but increasing gastrointestinal adverse events (AEs).

Pharmacokinetics

PK profiles of GLP-1 RAs dictate dosing regimens and therapeutic consistency. Semaglutide's extended half-life supports infrequent administration, but oral and SC routes differ in absorption and variability.

Absorption

SC semaglutide is slowly absorbed from the injection site, with Tmax ranging from 24-78 hours in healthy subjects and 30-56 hours in T2D patients, due to its depot-like release and albumin binding. This enables once-weekly dosing without food restrictions. Oral semaglutide, co-formulated with SNAC, achieves rapid gastric absorption (Tmax 0.8-1.75 hours), but bioavailability is low (~0.8%) owing to peptide instability in the GI tract. Absorption is highly sensitive to dosing conditions: fasting ≥6 hours pre-dose and ≥30 minutes post-dose with ≤120 mL water optimizes exposure; food co-administration reduces AUC by 32-40%.[4][5]

In special populations, oral absorption remains consistent in renal/hepatic impairment and upper GI disease, with no adjustments needed. Water volume impacts single-dose exposure (70% higher with 50 mL vs. 240 mL), but not steady state. Compared to other injectables, liraglutide has a shorter Tmax (8-12 hours), requiring daily dosing.

Distribution

Both formulations exhibit high albumin binding (>99%), restricting distribution to plasma and extracellular fluid (volume ~12-13 L). No significant racial differences after body weight adjustment. Distribution is not affected by route, but oral's variable absorption leads to higher inter-individual variability (CV 30-50% for AUC vs. 10-20% for SC).

Metabolism and Elimination

Semaglutide is metabolized via proteolytic cleavage and fatty acid beta-oxidation, independent of cytochrome P450. Half-life is ~1 week for both (153-161 hours oral; 145-168 hours SC), allowing accumulation to steady state over 4-5 weeks. Clearance is low (0.05 L/h), with metabolites excreted in urine (3%) and feces. No dose adjustments for renal (including ESRD) or hepatic impairment, as t1/2 remains similar or slightly prolonged in severe cases (221-243 hours SC).[4]

Drug interactions are minimal; semaglutide delays gastric emptying, potentially altering co-medication absorption (e.g., 32% increase in metformin AUC, but not clinically relevant). No interactions with warfarin, digoxin, or oral contraceptives.

Comparisons and Clinical Implications

Oral semaglutide requires higher doses (3-14 mg daily) for equivalent exposure to SC (0.25-1 mg weekly), with steady-state AUC lower in obese/T2D patients. Variability is higher orally, potentially affecting consistency if dosing instructions are ignored, unlike the reliable SC route. Network meta-analyses confirm comparable exposure-response, but SC may offer slight advantages in predictable delivery.[6][7]

Clinically, oral's fasting requirements may reduce adherence in real-world settings, while SC's convenience suits weekly regimens. Body weight reduces exposure for both, with implications for dosing in obesity.

Clinical Efficacy

Clinical trials and meta-analyses demonstrate robust efficacy of both formulations across T2D spectra, with SC often showing marginally superior outcomes in direct and indirect comparisons.

Glycemic Control

The PIONEER program (10 trials, >9500 patients) evaluated oral semaglutide (3-14 mg) in diverse settings. In PIONEER 1 (monotherapy), 14 mg reduced HbA1c by 1.4% vs. 0.1% placebo over 26 weeks, with 80% achieving <7% target.[8] PIONEER 2 (vs. empagliflozin) showed superiority at 52 weeks (-1.3% vs. -0.9%). PIONEER 3 (vs. sitagliptin) demonstrated dose-dependent superiority (-1.1% for 7 mg, -1.4% for 14 mg vs. -0.8%). PIONEER 4 (vs. liraglutide 1.8 mg) confirmed non-inferiority at 26 weeks (-1.2% vs. -1.1%) and superiority at 52 weeks (-1.2% vs. -0.9%). PIONEER 5 (renal impairment) and PIONEER 8 (add-on to insulin) showed reductions of 1.0-1.3% vs. placebo.[9][10]

The SUSTAIN program (10 trials) for SC semaglutide (0.5-1 mg) reported greater reductions: 1.5-1.8% in SUSTAIN 1-5 and 7, superior to sitagliptin, exenatide ER, dulaglutide, and insulin glargine. SUSTAIN 1 (monotherapy) achieved -1.45% for 0.5 mg, -1.55% for 1 mg vs. placebo. SUSTAIN 6 (CV outcomes) showed -1.0% reduction with sustained benefits.[11][12]

Meta-analyses indicate SC superiority for HbA1c (SMD 0.21, 95% CI 0.02-0.40), though real-world studies show similar effectiveness.[13][14] Target achievement (<7% HbA1c) is 55-77% oral vs. 66-80% SC.

Subgroup analyses reveal consistent efficacy across age, race, diabetes duration, and background therapy, with greater benefits in higher baseline HbA1c.

Weight Loss

Oral semaglutide induces 3.7-4.4 kg loss, superior to placebo (2.3-3.3 kg difference), sitagliptin, and liraglutide (-4.4 kg vs. -3.1 kg in PIONEER 4). In PIONEER 8, -3.7 kg with 14 mg add-on to insulin.[9]

SC semaglutide yields 4.5-6.5 kg, superior to comparators (e.g., -6.5 kg vs. dulaglutide -3.0 kg in SUSTAIN 7). Meta-analyses show non-significant greater loss with SC.[13] Real-world data confirm benefits, with sex-specific responses favoring SC in men.[15]

Cardiovascular and Renal Outcomes

PIONEER 6 demonstrated CV safety for oral semaglutide (HR 0.79 for MACE; nominal 51% reduction in CV death).[16] SUSTAIN 6 showed superiority for SC (HR 0.74 for MACE).[17] Meta-analyses confirm similar CV effects.[18] Renal benefits include reduced albuminuria and eGFR decline in both.

Quality of Life and Adherence

Both improve treatment satisfaction (DTSQ scores) and health status (SF-36). Oral preferences are high (76-91%) but drop with dosing awareness. Adherence is better with oral in some studies, though SC's weekly dosing aids compliance.

Safety and Tolerability

GI AEs are common: nausea (20%), diarrhea (15%), transient with dose escalation. Discontinuation is higher orally (RR 1.79 vs. SC).[13] Hypoglycemia is low (<5%), no increase with insulin add-on. No elevated risk of pancreatitis, thyroid cancer, or retinopathy beyond background.[19] Sex-specific data show similar tolerability.

Impact of Advanced Oral Delivery Systems

SNAC enables oral delivery by pH modulation and membrane permeation, achieving ~1% bioavailability without systemic SNAC exposure. This facilitates peptide oralization but mandates fasting, contrasting injectable flexibility. Emerging systems (e.g., exosomes) may enhance versatility.[5]

Conclusion

Oral semaglutide provides comparable pharmacology and efficacy to injectable GLP-1 RAs, with SC slightly superior in some metrics. Delivery systems enable oral access, improving patient choice. Future research should focus on adherence and long-term outcomes.[20]

References

1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.
2. Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45(5):409-418.
3. Dong S, Sun L, Xu J, et al. Clinical pharmacokinetics of semaglutide: A systematic review. Diabetes Metab Syndr Obes. 2024;17:2535-2548.
4. Buckley ST, Bækdal TA, Vegge A, et al. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with hepatic impairment. Clin Pharmacokinet. 2018;57(12):1571-1580.
5. Alcántara-Aragón V. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgrad Med. 2021;133(sup1):26-36.
6. Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528-540.
7. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50.
8. Knop FK, Aroda VR, do Vale Moreira NC, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719.
9. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258-266.
10. Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomised, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291-2301.
11. Alkhazaleh M, Alkhazaleh N, Alkhazaleh A, et al. Comparative effectiveness and safety of oral versus subcutaneous semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis. Cureus. 2024;16(10):e70857.
12. Di Mauro S, Greco C, Di Mauro S, et al. Real-world comparison of oral versus injectable semaglutide: Efficacy, adherence, and quality of life in type 2 diabetes patients. J Clin Med. 2024;13(21):6532.
13. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851.
14. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.
15. Mann JFE, Hansen T, Idorn T, et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(11):880-893.
16. Lingvay I, Catarig AM, Frias JP, et al. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER type 2 diabetes clinical trial programmes. Diabetes Obes Metab. 2023;25(5):1399-1412.
17. Buckley ST, Bækdal TA, Vegge A. Pharmacokinetics of oral and subcutaneous semaglutide: Why is the bioavailability of oral semaglutide so low? Clin Pharmacokinet. 2018;57(12):1593-1605.
18. Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the glucagon-like peptide-1 receptor agonist semaglutide administered orally to subjects with type 2 diabetes. Clin Pharmacokinet. 2018;57(12):1581-1591.
19. Wang X, Zhang Y, Chen L, et al. Oral delivery of semaglutide and tirzepatide using milk-derived extracellular vesicles: A promising approach for peptide therapeutics. J Extracell Biol. 2025;4(11):e70099.
20. Meier JJ. Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol (Lausanne). 2021;12:645617.
21. Dewasi G, Nagda P, Bahl G, Jain V, Gupta SK. Myostatin-driven muscle hypertrophy: a double-edged sword in muscle physiology. J Rare Dis. 2025;4(1):29. doi:10.1007/s44162-025-00086-x.
22. Tanwar CS, Jain V, Nagda P, Ramani K, Bahl G, Dewasi G, et al. A rare presentation of chronic lower back ache radiating to lower limb in a patient with ankylosing spondylitis with Andersson lesion managed by methotrexate: a case report. Research Square [Preprint]. 2025. doi:10.21203/rs.3.rs-6459382/v1.
23. Dewasi G, Nagda P, Jain S, Soni S. Pre-operative single 150 mg dose of pregabalin for postoperative pain management in laparoscopic cholecystectomy: a systematic review and meta-analysis. medRxiv [Preprint]. 2026. doi:10.64898/2026.07.11.26357848.